Synthetic Biologics, Inc.
(NYSE Amex Equities : SYN)

( )
SYN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.87%204.661.3%$437.29m
BIIBBiogen Inc.
0.13%226.061.3%$385.70m
GILDGilead Sciences, Inc.
1.23%65.300.9%$366.87m
CELGCelgene Corporation
0.56%100.951.3%$350.36m
ILMNIllumina, Inc.
0.60%312.173.5%$264.87m
REGNRegeneron Pharmaceuticals, Inc.
-0.53%303.822.6%$218.75m
EXASExact Sciences Corporation
5.16%99.7424.1%$209.91m
ALXNAlexion Pharmaceuticals, Inc.
3.42%104.812.0%$187.13m
VRTXVertex Pharmaceuticals Incorporated
1.47%176.141.9%$179.12m
AAgilent Technologies, Inc.
0.76%75.751.6%$150.80m
SRPTSarepta Therapeutics, Inc.
2.74%88.0514.6%$142.65m
ALDRAlder Biopharmaceuticals, Inc.
-0.21%18.8810.2%$128.87m
BMRNBioMarin Pharmaceutical Inc.
1.89%68.514.3%$96.67m
ACADACADIA Pharmaceuticals Inc.
1.72%40.1613.4%$89.24m
SGENSeattle Genetics, Inc.
1.17%83.386.2%$85.21m

Company Profile

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.